(2026). Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes. ACR Open Rheumatology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes."
ACR Open Rheumatology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes."
ACR Open Rheumatology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.